

Spojené kráľovstvo-Bristol: Patológia

OJ S 21/2020 30/01/2020

Oznámenie o dobrovoľnej transparentnosti ex ante
Služby

Právny základ:

Smernica 2014/24/EÚ

Oddiel I: Verejný obstarávateľ/obstarávateľ

I.1. Názov a adresy

Úradný názov: North Bristol NHS Trust

Poštová adresa: Southmead Road, Bristol

Mesto/obec: Bristol

Kód NUTS: UKK11 Bristol, City of

PSC: BS10 5NB

Štát: Spojené kráľovstvo

Kontaktná osoba: Martin Strawson

E-mail: martin.strawson@UH Bristol.nhs.uk

Telefón: +44 1173420815

Internetová adresa (internetové adresy):

Hlavná adresa: <https://www.nbt.nhs.uk/>

I.4. Druh verejného obstarávateľa

Iný druh: NHS trust

I.5. Hlavná činnosť

Zdravotníctvo

Oddiel II: Predmet

II.1. Rozsah obstarávania

II.1.1. Názov

Procurement of a Large Throughput DNA Sequencer

Referenčné číslo: BWPCCL001501

II.1.2. Hlavný kód CPV

85111800 Patológia

II.1.3. Druh zákazky

Služby

II.1.4. Stručný opis

The South West Genomic Hub Laboratory (SWGLH) based at North Bristol NHS Trust requires a large, high throughput DNA Sequencer for the processing new cancer panels at significant volume. The NovaSeq 6000 system provides the throughput, speed, and flexibility to complete next-generation sequencing (NGS) projects faster and more economically than ever before. A choice of 4 flow cell formats, multiple read length configurations, and the ability to run one or 2 flow cells simultaneously enable data output ranging from ~80 Gb-6000 Gb per run, providing flexibility across a broad range of applications and study sizes. The NovaSeq

6000 system combines unmatched system output with rapid run times to deliver the highest daily throughput of any NGS system currently available. With preconfigured reagent cartridges, RFID-encoded consumables, a choice between fully automated on board cluster generation and an individual lane loading workflow, the NovaSeq 6000 System provides simple, streamline.

II.1.6. Informácie o častiach

Táto zákazka sa delí na časti: nie

II.1.7. Celková hodnota obstarávania

Hodnota bez DPH: 779 625,00 GBP

II.2. Opis

II.2.2. Dodatočné kódy CPV

85111000 Nemocničné služby

II.2.3. Miesto vykonania

Kód NUTS: UKK11 Bristol, City of

II.2.4. Opis obstarávania

North Bristol NHS Trust is issuing this VEAT notice as the technical requirements of the high throughput next generation sequencing platform can only be met by one known supplier. North Bristol Trust is seeking a NGS sequencing system which will be able to process a high capacity of activity and to facilitate this intends to award a contract to Illumina Cambridge Ltd. NHS England has stated unequivocally that NHS cancer testing should move to a gene panel model. An investigation of the local testing portfolio suggests that > 70 % of the Trust's current range of tests could be condensed into a single gene panel. In this instance, the Trust would need the capacity to run in excess of 150 tests per week. The TTrust lacks the capacity to perform this volume of work on the current instruments, even if it did, the reagent costs would significantly exceed the costs of current testing.

To achieve the goal of efficient, cost effective workflows North Bristol Trust requires a very high capacity instrument to increase throughput, reduce turnaround times for reporting to molecular tumour boards, by purchasing a system that has a potential 1 day turnaround time (4 days for the full process DNA to data), generates up to 6 Tb of data (20 000 000 000 reads) per run and has cost effective reagent costs.

The NovaSeq would most likely be run in house using the S1 or S2 flowcells, with a capacity of 500 Gb or 1,25 Tb respectively. There are no other competing systems on the market with anything approaching this capacity. Switching to a 'universal' gene panel will allow an optimal workflow as all cancers will go on the same panel. This is likely to be around 500 genes. This is the only instrument on which the Trust could realistically run ctDNA sequencing for clinical purposes at sufficient depth to be clinically relevant.

Procurement to comprise:

Purchase of NovaSeq 6000 sequencing system with installation and training and 12 months warranty including parts and labour.

Purchase of Illumina Product Care NovaSeq 6000 comprehensive plan which includes full coverage for parts, labour and travel for 3 years contract.

II.2.5. Kritériá na vyhodnotenie ponúk

Kritérium kvality - Názov: Quality / Relatívna váha: 90

Cena - Relatívna váha: 10

II.2.11.

Informácie o opciách

Opcie: nie

II.2.13. Informácie o fondoch Európskej únie

Obstarávanie sa týka projektu a/alebo programu financovaného z fondov Európskej únie: nie

II.2.14. Doplnujúce informácie

Oddiel IV: Postup

IV.1. Opis

IV.1.1. Druh postupu

Pridelenie zákazky bez predchádzajúceho uverejnenia oznámenia o vyhlásení verejného obstarávania v Úradnom vestníku Európskej únie v prípadoch uvedených nižšie

- Zákazka nespadá do rozsahu uplatňovania smernice

Vysvetlenie:

North Bristol NHS Trust is issuing this VEAT notice as the technical requirements of the high throughput next generation sequencing platform can only be met by one known supplier. North Bristol Trust is seeking a NGS sequencing system which will be able to process a high capacity of activity and to facilitate this intends to award a contract to Illumina Cambridge Ltd. NHS England has stated unequivocally that NHS cancer testing should move to a gene panel model. An investigation of the local testing portfolio suggests that > 70 % of the Trust's current range of tests could be condensed into a single gene panel. In this instance, the Trust would need the capacity to run in excess of 150 tests per week. The TTrust lacks the capacity to perform this volume of work on the current instruments, even if it did, the reagent costs would significantly exceed the costs of current testing.

To achieve the goal of efficient, cost effective workflows North Bristol Trust requires a very high capacity instrument to increase throughput, reduce turnaround times for reporting to molecular tumour boards, by purchasing a system that has a potential 1 day turnaround time (4 days for the full process DNA to data), generates up to 6 Tb of data (20 000 000 000 reads) per run and has cost effective reagent costs.

The NovaSeq would most likely be run in house using the S1 or S2 flowcells, with a capacity of 500 Gb or 1,25 Tb respectively. There are no other competing systems on the market with anything approaching this capacity. Switching to a 'universal' gene panel will allow an optimal workflow as all cancers will go on the same panel. This is likely to be around 500 genes. This is the only instrument on which the Trust could realistically run ctDNA sequencing for clinical purposes at sufficient depth to be clinically relevant.

Procurement to comprise:

Purchase of NovaSeq 6000 sequencing system with installation and training and 12 months warranty including parts and labour.

Purchase of Illumina Product Care NovaSeq 6000 comprehensive plan which includes full coverage for parts, labour and travel for 3 years contract.

IV.1.3. Informácie o rámcovej dohode

IV.1.8. Informácie o dohode o vládnom obstarávaní (GPA)

Na toto obstarávanie sa vzťahuje dohoda o vládnom obstarávaní: nie

IV.2. Administratívne informácie

Oddiel V: Pridelenie zákazky/koncesie

Názov:

Procurement of Large High Throughput DNA Sequencer

V.2. Pridelenie zákazky/koncesie

V.2.1. Dátum rozhodnutia o zadaní zákazky

28/01/2020

V.2.2. Informácie o ponukách

Zákazka bola pridelená skupine hospodárskych subjektov: nie

V.2.3. Názov a adresa dodávateľa/držiteľa koncesie

Úradný názov: Illumina Cambridge Ltd

Poštová adresa: Chesterford Research Park, Little Chesterford

Mesto/obec: Saffron Walden

Kód NUTS: UKI London

PSC: CB10 1XL

Štát: Spojené kráľovstvo

Dodávateľom/koncesionárom bude MSP: áno

V.2.4. Informácie o hodnote zákazky/časti/koncesie

Celková hodnota zákazky/časti/koncesie: 779 625,00 GBP

V.2.5. Informácie o subdodávkach

Oddiel VI: Doplnkové informácie

VI.3. Doplnujúce informácie

VI.4. Postupy preskúmania

VI.4.1. Orgán zodpovedný za preskúmanie

Úradný názov: Bristol and Weston Purchasing Consortium

Poštová adresa: Level 3, Whitefriars, Lewins Mead

Mesto/obec: Bristol

PSC: BS1 2NT

Štát: Spojené kráľovstvo

E-mail: martin.strawson@UHBristol.nhs.uk

VI.4.2. Orgán zodpovedný za mediáciu

Úradný názov: Bristol and Weston Purchasing Consortium

Poštová adresa: Level 3, Whitefriars, Lewins Mead

Mesto/obec: Bristol

PSC: BS1 2NT

Štát: Spojené kráľovstvo

VI.4.4. Útvar, od ktorého možno získať informácie o postupe preskúmania

Úradný názov: Bristol and Weston Purchasing Consortium

Poštová adresa: Level 3, Whitefriars, Lewins Mead

Mesto/obec: Bristol

PSC: BS1 2NT

Štát: Spojené kráľovstvo

VI.5. Dátum odoslania tohto oznámenia

28/01/2020